Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

被引：0
|
作者：
Baz, Rachid [1 ]
Martin, Thomas G. [2 ]
Alsina, Melissa [1 ]
Shain, Kenneth H. [1 ]
Cho, Hearn J. [3 ]
Wolf, Jeffrey L. [2 ]
Mahindra, Anuj [2 ]
Chari, Ajai [3 ]
Sullivan, Daniel M. [4 ]
Nardelli, Lisa A. [1 ]
Lau, Kenneth [3 ]
Zhao, Xiuhua [1 ]
Lin, Hui-Yi [1 ]
Jagannath, Sundar [3 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Weisel, Katja
    Bentur, Ohad
    Van Domelen, Dane
    Boccadoro, Mario
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
  • [22] Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
    Garderet, Laurent
    Polge, Emmanuelle
    Gueye, Mor Seny
    Kellil, Chaima
    Ova, Jeanny Guelongo Okouango
    Beohou, Eric
    Labopin, Myriam
    Mohty, Mohamad
    BLOOD, 2015, 126 (23)
  • [23] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [24] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
    Bringhen, Sara
    Magarotto, Valeria
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Gilestro, Milena
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Stocchi, Raffaella
    Ribolla, Rossella
    Di Sano, Chiara
    Patriarca, Francesca
    Passera, Roberto
    De Paoli, Lorenzo
    Oliva, Stefania
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    BLOOD, 2016, 128 (22)
  • [26] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [27] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
  • [28] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [29] A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Schroeder, Mark A.
    Berenson, James R.
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Voorhees, Peter M.
    Fujii, Hisaki
    Yang, Zhao
    Galimi, Francesco
    Shain, Kenneth H.
    BLOOD, 2018, 132
  • [30] OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide
    Sonneveld, Pieter
    Schjesvold, Fredrik
    Robak, Pawel
    Rossjey, Viktor
    Pour, Ludk
    Minarik, Jiri
    Delimpasi, Sosana
    Legic, Wojciech
    Salogub, Galina
    Harmenberg, Johan
    Byrne, Catriona
    Nordstrom, Eva
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S25 - S25
12345